LEADER 02294nam  2200601 a 450 
001 9910220124103321
005 20240516210422.0
010   $a0-8330-7646-9
035   $a(CKB)2670000000232840
035   $a(EBL)981579
035   $a(OCoLC)804665552
035   $a(SSID)ssj0000870484
035   $a(PQKBManifestationID)11463549
035   $a(PQKBTitleCode)TC0000870484
035   $a(PQKBWorkID)10818478
035   $a(PQKB)10643748
035   $a(MiAaPQ)EBC981579
035   $a(Au-PeEL)EBL981579
035   $a(CaPaEBR)ebr10583965
035   $a(OCoLC)893183697
035   $a(EXLCZ)992670000000232840
100   $a20120810d2012      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aMedicines as a service$b[electronic resource] $ea new commercial model for big pharma in the postblockbuster world /$fSoeren Mattke, Lisa Klautzer, and Tewodaj Mengistu
205   $a1st ed.
210   $aSanta Monica, Calif. $cRAND$dc2012
215   $a1 online resource (12 p.)
225 1 $aRAND Health occasional paper
300   $aDescription based upon print version of record.
320   $aIncludes bibliographical references.
327   $aMedicines as a Service
330   $aThe pharmaceutical industry can reconfigure its considerable resources to develop innovative and meaningful business models that are based on services that improve access and adherence to prescription drugs for common chronic conditions. Such innovation beyond drug development is consistent with the core capabilities of large pharmaceutical companies and has the potential to achieve profit levels similar to those of its traditional models.
410  0$aOccasional paper (Rand Corporation)
606   $aPharmaceutical services
606   $aPharmaceutical industry
615  0$aPharmaceutical services.
615  0$aPharmaceutical industry.
676   $a362.29/90941
700   $aMattke$b Soeren$0851848
701   $aKlautzer$b Lisa$0924081
701   $aMengistu$b Tewodaj$0924082
712 02$aRAND Health.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910220124103321
996   $aMedicines as a service$92073800
997   $aUNINA